Clinical analysis of elderly patients with hyperkalemia during combined therapy of ACEI and spironolactone
- VernacularTitle:血管紧张素转换酶抑制剂和安体舒通联用发生高钾血症的临床分析
- Author:
Xutao SUI
;
Jingli CHI
;
Hongying CANG
- Publication Type:Journal Article
- Keywords:
Hyperkalemia;
Angiotensin-converting enzyme inhibitors;
Drug therapy, combination
- From:
Chinese Journal of Geriatrics
2001;0(05):-
- CountryChina
- Language:Chinese
-
Abstract:
6 mmol/L) and treated with ACEI and spirolactone were included in this study. Patients were followed up for at least one month after admission. Results The mean age of the patients (9 males, 13 famales) was (72?11) years old. Four of them were diabetics. On admission, the serum potassium was (7.3?0.8) mmol/L and serum creatinine was (318.2?150.3) ?mol/L; these values were significantly higher than the most recent laboratory measurements (4.5?0.6) mmol/L and (159.1?114.9) ?mol/L, respectively obtained (11?4) weeks before admission. Out of these patients, 19 suffered from acute renal failure and the main causes were dehydration (n=11) and severe heart failure (n=8). The mean daily dosage of spironolactone was (48?27) mg. Among them 11 were concomitantly treated with other drugs that might cause hyperkalemia, and finally 1 patient died and 8 patients were treated by hemodialysis. Conclusions A combination treatment of ACEI and spironolactone should be considered with caution and serum potassium level should be monitored closely in patient with renal insufficiency, hyperkalemia, severe heart failure, diabetes, especially in those elder patients. Daily dosage of spironolactone should not be over 20 mg.
